Florida’s Vertical Integration Model Makes One Licence Carry the Whole Supply Chain

Florida does not license its medical cannabis supply chain one stage at a time. It licenses a medical marijuana treatment centre, then requires that business to carry the product from cultivation through processing, transport and dispensing.

That is the central fact of Florida’s vertical integration model. It means the state’s 771 approved dispensing locations are not 771 independent retailers buying from a broad field of growers and manufacturers. They are outlets attached to a much smaller group of treatment-centre licences that control the upstream product sold through their own networks.

The Florida Office of Medical Marijuana Use listed 28 currently licensed medical marijuana treatment centres in its public FAQ in August 2026. Its July 31 weekly report showed 22 licensees with at least one dispensing location, three with zero, and three whose location field was not applicable. The same report counted 938,980 qualified patients with active identification cards.

The legal requirement is explicit

Section 381.986 of the Florida Statutes says a licensed treatment centre shall cultivate, process, transport and dispense marijuana for medical use. The law generally bars centres from contracting out services directly related to cultivation, processing and dispensing. It also prohibits wholesale purchases from, or distribution to, another treatment centre unless the buyer submits proof of harvest failure to the Department of Health.

This is much tighter than a market in which separate grow, manufacturing, distribution and retail licences can trade with one another. A Florida company cannot enter only as a plant-touching manufacturer and sell products across independent dispensary shelves. A retailer cannot build an assortment by purchasing from any licensed producer in the state. The treatment centre is the supply chain.

Independent testing is an important exception to the integrated structure. Treatment centres must contract with certified marijuana testing laboratories, and those laboratories operate under a separate state certification framework. The model therefore integrates commercial production and sale while retaining third-party laboratory review.

One licence can support a large retail network

Florida’s weekly report makes the scale differences visible. For the week ending July 30, one treatment centre operated 170 dispensing locations. The next three operated 86, 75 and 65. Together, those four networks accounted for 396 locations, just over half of the statewide total.

At the other end of the table, several licensed centres had not opened a dispensing location. The licence count therefore overstates the number of active competitors, while the store count overstates the number of independent retail buying organisations.

This is a structural form of concentration. It does not mean every shop carries an identical menu or that every licensee has the same production capacity. It means retail expansion can occur through additional locations under an existing treatment-centre system instead of through a new standalone retailer entering the market.

Local government has a defined but limited role. A county or municipality may ban dispensing facilities. If it does not ban them, Florida law says it may not impose a specific numerical cap on dispensing facilities. Local rules generally may not be more restrictive than the jurisdiction’s rules for pharmacies, although school-distance and other statutory requirements still apply.

The result is a statewide licensing bottleneck paired with potentially broad local store networks. Competition for the licence is narrow; competition among the locations of existing licensees can be extensive.

Patient growth triggers licences, not open entry

The statute ties expansion of the treatment-centre pool to patient registration. After specified initial licensing steps, the Department of Health is directed to license four additional treatment centres within six months after each additional 100,000 active qualified patients are registered.

That formula does not create automatic open entry. Applicants must win a limited licence and demonstrate the ability to operate the integrated system. Statutory requirements include technical ability, secure premises and personnel, inventory accountability, dispensing infrastructure, background screening and financial capacity. An approved applicant generally must post a $5 million performance bond; a centre serving at least 1,000 patients may maintain a $2 million bond instead.

Those requirements put capital needs at the centre of the market design. A prospective operator is not financing one retail shop or one processing line. It is presenting the state with a plan for a compliant, traceable system that spans production and statewide or regional patient access.

What vertical integration changes for operators

For a treatment-centre licensee, integration provides control. Cultivation plans, processing schedules, inventory allocation, delivery and retail pricing can be coordinated within one organisation. The same control also concentrates execution risk. A crop problem or processing interruption cannot normally be solved by routine wholesale purchasing from another Florida producer. The statute’s harvest-failure exception is narrow, not an ordinary open wholesale market.

For product businesses, the route to Florida shelves runs through a treatment centre. Intellectual property, branding or non-plant-touching services may be commercialised through contracts that comply with state rules, but the regulated cannabis itself must remain within the licensee’s authorised system. Florida is therefore not a market where an out-of-state brand can simply obtain a manufacturing licence and sell through unrelated retailers.

For retailers, assortment is inseparable from the integrated operator’s cultivation and processing capacity. That can strengthen traceability from product back to the licensee, but it also limits the number of independent suppliers competing for shelf space. Consumers choose among treatment-centre networks rather than among stores sourcing from a common wholesale exchange.

What the weekly numbers do and do not show

Florida reports weekly dispensations in milligrams of active THC for medical marijuana, milligrams of CBD for low-THC cannabis, and ounces for marijuana in a form for smoking. For July 24 through July 30, 2026, OMMU reported 423.5 million milligrams of medical-marijuana THC and 146,369.661 ounces of smoking-form marijuana dispensed.

Those are product quantities, not retail revenue. They cannot be converted into a reliable statewide sales figure without transaction prices and product-level context. The data are still valuable because they show the operating scale attached to each integrated licence and the distribution of storefronts across the licensee pool.

Florida’s programme is large by patient count and retail reach, but its basic unit of competition is not the dispensary. It is the treatment centre. Any assessment of market share, new entry or brand access that begins with 771 storefronts and ignores the 28 licences behind them will misread how the state works.